ChemoCentryx Inc (NASDAQ:CCXI) insider Plc Glaxosmithkline sold 7,343,492 shares of the stock in a transaction dated Tuesday, October 16th. The stock was sold at an average price of $11.69, for a total value of $85,845,421.48. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Shares of ChemoCentryx stock traded down $1.65 during trading on Friday, hitting $10.05. 340,471 shares of the stock traded hands, compared to its average volume of 164,306. The company has a current ratio of 2.69, a quick ratio of 2.69 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $603.72 million, a PE ratio of 27.92 and a beta of 1.78. ChemoCentryx Inc has a 52 week low of $5.42 and a 52 week high of $15.08.
ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. ChemoCentryx had a return on equity of 39.31% and a net margin of 18.69%. The firm had revenue of $8.98 million for the quarter, compared to analyst estimates of $11.55 million. As a group, analysts predict that ChemoCentryx Inc will post -0.86 earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of CCXI. Strs Ohio lifted its stake in shares of ChemoCentryx by 8.5% in the 2nd quarter. Strs Ohio now owns 60,200 shares of the biopharmaceutical company’s stock valued at $792,000 after purchasing an additional 4,700 shares during the period. P.A.W. Capital Corp raised its stake in ChemoCentryx by 5.9% during the third quarter. P.A.W. Capital Corp now owns 90,000 shares of the biopharmaceutical company’s stock valued at $1,138,000 after buying an additional 5,000 shares during the last quarter. American Century Companies Inc. raised its stake in ChemoCentryx by 3.2% during the third quarter. American Century Companies Inc. now owns 169,037 shares of the biopharmaceutical company’s stock valued at $2,137,000 after buying an additional 5,166 shares during the last quarter. Trexquant Investment LP raised its stake in ChemoCentryx by 47.4% during the second quarter. Trexquant Investment LP now owns 17,056 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 5,482 shares during the last quarter. Finally, Sei Investments Co. raised its stake in ChemoCentryx by 203.5% during the second quarter. Sei Investments Co. now owns 8,549 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 5,732 shares during the last quarter. Hedge funds and other institutional investors own 53.18% of the company’s stock.
A number of brokerages recently issued reports on CCXI. ValuEngine cut ChemoCentryx from a “buy” rating to a “hold” rating in a report on Thursday, September 27th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of ChemoCentryx in a report on Monday, August 13th. BidaskClub cut ChemoCentryx from a “buy” rating to a “hold” rating in a report on Thursday, July 19th. B. Riley initiated coverage on ChemoCentryx in a report on Friday, September 7th. They issued a “neutral” rating and a $12.50 price target on the stock. Finally, Zacks Investment Research cut ChemoCentryx from a “strong-buy” rating to a “hold” rating in a report on Monday, July 16th. Five equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $16.58.
TRADEMARK VIOLATION WARNING: This story was originally reported by Equities Focus and is the property of of Equities Focus. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.equitiesfocus.com/2018/11/10/chemocentryx-inc-ccxi-insider-plc-glaxosmithkline-sells-7343492-shares-of-stock.html.
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
Featured Story: Stop Order
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.